The 20 Most Disruptive Healthcare Solution providers The 20 Most Disruptive Healthcare Solution Provide | Page 30

Genpharm A Foremost Pharmaceutical Organization Offering Tailor-made and Comprehensive Solutions G enpharm is a leading regional pharmaceutical market access and marketing company focused mainly on niche therapeutics and diagnostics for rare genetic diseases. The company has partnered with multinational companies that have evidence-based and innovative drugs looking to expand into the Middle East and North Africa (MENA) region. The company operates through an experienced and dedicated team of medical science liaisons and key account managers. The company’s partnerships are based on long-term regional commercial agreements or in-licensing deals under the Genpharm brand. Outshining with its Diverse Services Genpharm offers its expertise to achieve fast market access for companies looking to expand into the Middle East region. Being the exclusive partner for pharmaceutical organizations, it offers every required service to its clients at the highest standards which include regulatory, medical and pharmacovigilance support, quality and logistics, market access (pricing and reimbursement). It also dedicates field staff for them to work closely with the key stakeholders on disease awareness, patient support programs, CME events, scientific meetings, advisory boards and expert panels. Karim Smaira Founder & MP ” Genpharm was established by the two influential Founders & Managing Partners, Karim Smaira and Kamel Ghammachi, whose leadership has been a consistent presence in the MENA pharmaceutical sector for over forty years. They both have successfully occupied several industry roles and managed large multinational pharmaceutical organizations in both regional and international functions. Kamel Ghammachi Founder & MP Our mission is to provide healthcare organizations with innovative therapeutic solutions in niche and rare genetic disease areas, market access strategies and sustainable commercial solutions ” |November 2018 | 28